"当前创新药销售费用中，基本医保承担44%，商业保险承担7%，其余近半数需由患者自费或通过其他 途径解决。"国家医疗保障局医药管理司司长黄心宇在医保目录解读会上公布的这组数据，直指创新药 支付端的现实痛点。 2026年以来，创新药产业迎来政策密集赋能，支付体系优化与药品可及性提升的双重利好同步落地，国 家打通创新药落地"最后一公里"的力度空前。1月1日，2025年新版国家医保药品目录与首版商保创新药 目录在全国正式实施；1月22日，商务部等9部门联合印发《关于促进药品零售行业高质量发展的意 见》，明确鼓励创新药、参比制剂等进入零售药店销售渠道。一系列新政落地，正从支付、渠道等多维 度重构创新药行业生态，为产业发展注入全新动力。 一次规模扩容 2025年新版国家医保药品目录的调整，堪称医保目录诞生以来创新药规模最大的一次扩容。黄心宇介 绍，本次目录新增114种药品，同步调出29种临床无供应或可被更好替代的药品，新增药品111种为5年 内新上市品种、50种为I类新药，数量与占比均创历年新高。 此次新增的医保药品，均具备填补临床空白、同类疗效更优、性价比突出三大核心特征，精准对接临床 未满足的治疗需求。黄心宇说：" ...

Core Insights - The new national medical insurance drug list and the first commercial insurance innovative drug list will be implemented nationwide starting January 1, 2026, marking the largest expansion of innovative drugs in the history of the medical insurance directory [1] - The adjustment of the medical insurance directory represents a dual benefit for the innovative drug industry in China, with significant changes in the inclusion of innovative drugs and the establishment of a commercial insurance innovative drug directory [1][2] Summary by Sections Innovative Drug Inclusion - A total of 114 new drugs have been added to the national medical insurance drug list, including 111 new products launched within the last five years and 50 Class I new drugs, both of which set historical highs in terms of quantity and proportion [1][2] - The newly included drugs generally possess three common characteristics: they either fill a treatment gap, are superior alternatives, or offer better cost-effectiveness [2] Commercial Insurance Innovative Drug Directory - The first commercial insurance innovative drug directory includes 19 drugs, covering treatments for various conditions such as CAR-T therapies for tumors, rare diseases like Gaucher disease, and Alzheimer's disease, complementing the basic medical insurance [2][3] - The selection mechanism for the commercial insurance directory emphasizes high innovation, significant clinical value, strong irreplaceability, and adaptability to a multi-tiered payment system [3] Payment System and Market Impact - The medical insurance fund has paid over 460 billion yuan for negotiated drugs by the end of October 2025, benefiting 1 billion patients and driving related drug sales exceeding 670 billion yuan [4] - The new dual-directory system aims to clarify the boundaries of basic medical insurance coverage while allowing space for commercial insurance development, thus supporting a multi-tiered payment system [3][4] Innovation Ecosystem - The integration of the commercial insurance innovative drug directory with the national medical insurance drug list is crucial for building a multi-layered medical security system, focusing on high-innovation and clinically significant drugs that exceed basic insurance coverage [5] - The successful inclusion of breakthrough therapies like Alpelisib not only provides hope for patients but also signals strong support for genuine innovation within the pharmaceutical industry [5]

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][2]. Group 1: Drug Catalog Adjustments - The updated basic medical insurance catalog includes 114 new drugs, with significant representation from oncology (36 drugs), chronic diseases (12 drugs), anti-infectives (13 drugs), and rare diseases (10 drugs) [2]. - The total number of drugs in the national medical insurance catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2]. - The adjustment aims to address clinical treatment gaps and enhance drug accessibility for patients, particularly for previously hard-to-treat conditions like triple-negative breast cancer and pancreatic cancer [2][4]. Group 2: Policy Implementation - A combination of policies will ensure that newly added drugs are available in hospitals by February 2026, including the establishment of temporary green channels for procurement [3]. - Negotiated drugs will not be subject to administrative restrictions such as "one product, two regulations" or overall medical insurance caps, allowing for more flexible access [3]. Group 3: Support for Innovation - Among the new drugs, 50 are classified as first-class innovative drugs, with an overall success rate of 88%, up from 76% in 2024, indicating a shift towards strategic purchasing and value-based reimbursement [4]. - The inclusion of both domestic and foreign innovative products in the catalog reflects a commitment to enhancing drug accessibility and supporting pharmaceutical innovation [4]. Group 4: Commercial Health Insurance - The newly established commercial health insurance innovative drug catalog includes 19 drugs, focusing on high-innovation, clinically valuable treatments that complement the basic medical insurance offerings [7]. - The catalog features advanced therapies such as CAR-T cell treatments and drugs for rare diseases, which are expected to reduce patient financial burdens and enhance market attractiveness for pharmaceutical companies [7][8]. Group 5: Future Directions - The policy signals strong government support for independent innovation and aims to encourage pharmaceutical companies to invest more in original and differentiated research and development [8]. - The National Medical Insurance Administration plans to refine policies and strengthen management to ensure the effective implementation of the drug catalogs, enhancing public access to necessary medications [8].

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][6] Group 1: Drug Catalog Adjustments - The adjustment of the National Medical Insurance Drug Catalog adheres to principles of supporting genuine innovation and differentiated innovation, aiming to meet diverse medication needs and enhance accessibility to high-value innovative drugs [1][2] - The updated catalog includes 36 cancer drugs, 12 chronic disease medications, 13 anti-infection drugs, and 10 rare disease treatments, increasing the total number of drugs in the catalog to 3,253 [1][2] - The inclusion of 50 first-class innovative drugs reflects a significant increase in the success rate of new drug approvals, rising from 76% in 2024 to 88% in 2025 [3][4] Group 2: Policy Implementation and Impact - The National Medical Insurance Bureau has adjusted the drug catalog for eight consecutive years, adding a total of 949 new drugs, with expenditures exceeding 460 billion yuan and sales exceeding 600 billion yuan during the negotiation period [2][3] - New policies require medical institutions to include newly added drugs in their procurement lists by the end of February 2026, addressing the issue of drugs being listed but not available in hospitals [2][3] Group 3: Commercial Health Insurance Innovative Drug Catalog - The first Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, primarily high-innovation and clinically valuable treatments, which complement the basic medical insurance offerings [6][7] - The catalog features advanced therapies such as CAR-T cell treatments and bispecific antibodies, targeting rare diseases prevalent in children, thus expanding market opportunities for pharmaceutical companies [6][7] Group 4: Industry Response and Future Outlook - The policy sends a clear signal of government support for independent innovation, encouraging pharmaceutical companies to invest more in original and differentiated research and development [7] - The National Medical Insurance Bureau plans to refine policies and enhance management to ensure the effective implementation of the drug catalogs, ultimately improving the clinical medication experience for insured individuals [7]

Core Insights - The new National Medical Insurance Drug List and Commercial Health Insurance Innovative Drug List will be implemented in Wuhan starting January 1, 2026, focusing on "clinical urgency, affordability, and diverse coverage" [1] - The updated list includes 114 new drugs, with a significant emphasis on oncology and rare diseases, complementing the basic medical insurance coverage [2][5] Summary by Sections New Drug Inclusion - The revised National Medical Insurance Drug List now includes a total of 3,253 drugs, with 1,857 Western medicines and 1,396 traditional Chinese medicines [2] - Among the 114 newly added drugs, 50 are classified as innovative drugs, achieving a high inclusion success rate of 88%, with over 90% being newly approved in the last five years [2] Price Reductions - The average price reduction for the newly included drugs is 63%, with some high-profile drugs seeing reductions exceeding 70% [3] - For instance, the monthly cost of the drug Tirzepatide, previously between 1,700 to 2,000 yuan, is now reduced to 324.1 yuan for the 2.5 mg dosage and 936.7 yuan for the 10 mg dosage, significantly lowering the annual burden for patients in Wuhan by over 15,000 yuan [3] Commercial Health Insurance Innovations - The first edition of the Commercial Health Insurance Innovative Drug List includes 19 high-value innovative drugs, addressing gaps in basic medical insurance coverage [5] - This list features CAR-T cell therapy drugs and treatments for rare diseases, with some therapies costing over 400,000 yuan annually [5] Dual-Channel System Expansion - The dual-channel drug list has expanded to 621 drugs, significantly increasing from the previous version [7] - This includes 321 drugs for targeted therapies, rare diseases, infectious diseases, and mental health, with specific policies for outpatient special diseases to ensure precise benefit delivery [7] Streamlined Processes - All designated retail pharmacies in Wuhan have implemented electronic prescription systems, allowing patients to choose between hospital pharmacies and designated stores for immediate reimbursement [7] - The new system aims to enhance efficiency and reduce patient wait times, promoting a more convenient healthcare experience [7] Collaboration and Communication - Wuhan is establishing a continuous communication platform between pharmaceutical companies and medical institutions to facilitate the understanding of new drug characteristics and supply [8] - By February 2026, all medical institutions are required to adjust their drug procurement processes to ensure the availability of newly negotiated drugs [8]

Core Insights - The new National Medical Insurance Drug List and the first Commercial Insurance Innovative Drug List have been officially released, including over a hundred innovative drugs, set to be implemented on January 1 next year [1] Group 1: New Drugs Included in the Medical Insurance List - 98% of the drugs included in the medical insurance list are new drugs approved within the last five years, with 50 of them being first-class new drugs, marking a historical high [2] - A significant portion of the newly added drugs addresses high-demand conditions such as cancer, chronic diseases, and rare diseases, with 36 cancer drugs included, accounting for approximately 30% of the total [2] - The inclusion of innovative drugs is expected to alleviate clinical pain points, particularly for conditions previously lacking effective treatments, such as triple-negative breast cancer and pancreatic cancer [3] Group 2: Coverage and Clinical Value - The new medical insurance directory covers a wide range of diseases, including metabolic diseases and rare diseases, with drugs like KARS-targeted therapies now included [3] - Chronic disease medications, such as the cholesterol-lowering drug Increlex and the dual-target diabetes drug Tirzepatide, have also been added to the list [4] - The approval rate for drugs entering the expert review stage has decreased to 41.48%, with 331 drugs evaluated and only 129 passing the review [5] Group 3: Criteria for Inclusion - The "Four No Changes" principle restricts the inclusion of drugs that do not alter the main components, indications, administration routes, or clinical value, focusing on "true innovative" drugs that fill existing gaps [6] - Several first-class new drugs did not pass the expert review due to insufficient clinical value, despite being new compounds [7] - Experts emphasize the need to avoid homogenized innovation that wastes resources, advocating for genuine innovation that demonstrates real clinical benefits [8] Group 4: Commercial Insurance Innovative Drug List - The first Commercial Insurance Innovative Drug List includes advanced therapies such as CAR-T cell therapy, monoclonal antibodies, and small molecule targeted drugs, with 19 drugs included [10] - To facilitate the implementation of the commercial insurance innovative drug list, the National Medical Insurance Bureau has provided supportive measures, including exemptions from certain monitoring and payment frameworks [11] - The successful implementation of this new system requires careful consideration of actuarial pricing and the establishment of efficient communication platforms between commercial insurance and medical enterprises [11]

Core Viewpoint - The article discusses the recent update of China's National Medical Insurance Drug List, which includes 114 new drugs, highlighting the introduction of a commercial health insurance innovative drug directory alongside the basic insurance list, aiming to enhance patient access to innovative treatments and address gaps in drug coverage [6][13]. Group 1: New Drugs in the National Medical Insurance Directory - A total of 114 new drugs have been added to the directory, covering various treatment areas including 36 for tumors, 12 for chronic diseases, and 10 for rare diseases, with the number of class 1 new drugs increasing from 38 to 50, setting a new historical high [6][7]. - Notable "star drugs" include LuKangsa Tazhu (for tumors), Fluorazirase tablets, and Spilumab (for specific dermatitis), which will benefit a wide range of patients, including those with triple-negative breast cancer and chronic sinusitis [7][8]. Group 2: Financial Impact on Patients - The average price reduction for negotiated drugs has historically been around 60%, with 112 out of 127 drugs successfully negotiated this year, resulting in significant cost savings for patients [9]. - The introduction of Spilumab, priced at around 1,000 yuan per injection, is expected to significantly lower the financial burden on patients, making innovative treatments more accessible [9]. Group 3: Implementation Challenges - There are concerns regarding the "last mile" issue in drug availability at hospitals, as many negotiated drugs are still provided through external pharmacies, and hospitals may hesitate to prescribe these due to cost concerns [10][11]. - The new regulations require that hospitals must not limit the availability of negotiated drugs based on overall budget constraints, ensuring that these drugs are accessible to patients [11]. Group 4: Changes in the Drug Directory - This year, 29 drugs were removed from the directory due to being replaced or not produced, with a total of 467 drugs removed over the past eight years for similar reasons [12]. - A six-month transition period has been established for patients using drugs that are not renewed in the directory, ensuring continuity of care [12]. Group 5: Commercial Health Insurance Innovative Drug Directory - The newly established commercial health insurance innovative drug directory includes 19 drugs, focusing on high-value innovative treatments that cannot be covered by the basic insurance directory [13][15]. - The drugs in this directory are characterized by high innovation, significant clinical value, and the need for diverse payment options, with 50% being class 1 new drugs [15]. Group 6: Benefits for Patients - The commercial health insurance directory aims to provide a curated list of high-quality drugs, reducing the selection burden for insurance companies and potentially lowering costs for patients through reduced premiums or increased reimbursement rates [16]. - The integration of the commercial insurance directory with existing medical insurance systems is being explored to enhance patient experience and access to innovative treatments [16]. Group 7: Future Prospects and Challenges - The implementation of the commercial health insurance innovative drug directory is dependent on market mechanisms, with insurance companies determining the usage and timing of these drugs [19]. - Emphasis on actuarial pricing and collaboration between insurance companies and pharmaceutical firms is crucial for the sustainable rollout of these innovative drugs [19].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative return of over 20% within the next six months [7]. Core Insights - The company achieved a total revenue of 9.42 billion RMB in 2024, representing a year-on-year growth of 51.8%. Product revenue reached 8.23 billion RMB, up 43.6% year-on-year. The company also reported its first positive Non-IFRS profit of 330 million RMB and an EBITDA of 410 million RMB, with IFRS losses narrowing by 90.8% [1]. - The company has seen a decrease in various expense ratios, with sales expenses at 4.347 billion RMB (46.14% of revenue, down 3.83 percentage points), R&D expenses at 2.681 billion RMB (28.45%, down 7.45 percentage points), and administrative expenses at 738 million RMB (7.83%, down 4.25 percentage points). This reduction in expense ratios is attributed to significant revenue growth [2]. - The company is expected to launch six new drugs in 2025, with one drug entering the medical insurance system. Several products are nearing commercialization, which will serve as a significant growth driver. Recently, five new products were approved for market, including drugs targeting various cancers and conditions [3]. - The company has promising products in the pipeline, particularly in the weight loss sector with the drug Masitide, which is expected to yield data from ongoing studies by the end of 2025. In oncology, early data from several products have shown strong potential, with international clinical trials underway [4]. - Revenue forecasts for 2025-2026 have been revised upwards, with expected revenues of 11.518 billion RMB and 14.721 billion RMB, respectively. Net profit estimates for the same period have also been increased to 515 million RMB and 1.830 billion RMB. The revenue for 2027 is projected to reach 20.020 billion RMB, with net profit expected at 3.109 billion RMB [5].